Rimm D.L.,Yale University |
Rimm D.L.,Ohio State University |
Rimm D.L.,Cancer and Leukemia Group B Pathology Coordinating Office |
Rimm D.L.,Cleveland Clinic |
And 356 more authors.
Journal of Clinical Oncology | Year: 2011
Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population. © 2011 by American Society of Clinical Oncology.